An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug Resistance …, 2021 - Elsevier
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

[HTML][HTML] Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 …

S Cesaro, P Ljungman, M Mikulska, HH Hirsch… - Leukemia, 2022 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS …

L Bouadma, A Mekontso-Dessap, C Burdet… - JAMA internal …, 2022 - jamanetwork.com
Importance The benefit of high-dose dexamethasone and oxygenation strategies vs
standard of care for patients with severe acute hypoxemic respiratory failure (AHRF) caused …

[HTML][HTML] Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID …

A Granholm, MW Munch, SN Myatra… - Intensive care …, 2022 - Springer
Purpose We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients
with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international …

Dexamethasone: insights into pharmacological aspects, therapeutic mechanisms, and delivery systems

VS Madamsetty, R Mohammadinejad… - ACS biomaterials …, 2022 - ACS Publications
Dexamethasone (DEX) has been widely used to treat a variety of diseases, including
autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19 …

[HTML][HTML] Randomised clinical trials in critical care: past, present and future

A Granholm, W Alhazzani, LPG Derde, DC Angus… - Intensive care …, 2022 - Springer
Randomised clinical trials (RCTs) are the gold standard for providing unbiased evidence of
intervention effects. Here, we provide an overview of the history of RCTs and discuss the …

[HTML][HTML] Pharmacological treatment of COVID-19: an opinion paper

A García-Lledó, J Gómez-Pavón… - Revista Española de …, 2022 - ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …

[HTML][HTML] Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised …

RECOVERY Collaborative Group - Lancet (London, England), 2023 - ncbi.nlm.nih.gov
Background Low-dose corticosteroids have been shown to reduce mortality for patients with
COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation …

[HTML][HTML] Comparison of COVID-19 induced respiratory failure and typical ARDS: similarities and differences

S Lu, X Huang, R Liu, Y Lan, Y Lei, F Zeng… - Frontiers in …, 2022 - frontiersin.org
Coronavirus disease 2019 (COVID-19) is a predominantly respiratory infectious disease
caused by novel coronavirus infection (SARS-CoV-2), respiratory failure is the main clinical …

[HTML][HTML] COVID-19 annual update: a narrative review

M Biancolella, VL Colona, L Luzzatto, JL Watt… - Human genomics, 2023 - Springer
Three and a half years after the pandemic outbreak, now that WHO has formally declared
that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on …